Alzamend Neuro is trading 6.79% down now at $1.37 after no clear company-specific catalyst was identified for August 12, 2026.
- The latest notable filing-related news was the August 4 announcement of a $7.5 million initial tranche within a potential $25 million Series D convertible preferred-stock financing.
- Additional planned tranches may remain an overhang, but available coverage does not explicitly link the financing to this pre-market decline.